Concepedia

Fluorine-18 Prostate-Specific Membrane Antigen–1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer

Nikhile Mookerji, Tyler Pfanner, Amaris Hui, Guocheng Huang, Patrick Albers, Rohan Mittal, Stacey Broomfield, Lucas Dean, Blair St. Martin, Niels-Erik Jacobsen,

JAMA Oncology · 2024 · 32 citations · 12 references

DOIFull text

Open access

Abstract

In this phase 2 prospective validating paired cohort study, 18F-PSMA-1007 PET/CT was superior to MRI for the locoregional staging of prostate cancer. These findings support PSMA PET in the preoperative workflow of intermediate-risk and high-risk tumors.

References

12

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet, Joaquim Bellmunt, M. Bolla et al. · European Urology · 2016 · 3.2K citations · Full text

, , +6

STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies

Patrick M. Bossuyt, Johannes B. Reitsma, David E. Bruns et al. · BMJ · 2015 · 3.1K citations · Full text

, , +19

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al. · The Lancet · 2020 · 1.8K citations

, , +12

Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer

Wolfgang P. Fendler, Jérémie Calais, Matthias Eiber et al. · JAMA Oncology · 2019 · 749 citations · Full text

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

Frederik L. Giesel, Boris Hadaschik, Jens Cardinale et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 573 citations · Full text